Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
immunoglobulins · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| intravenous immunoglobulins (IVIG) | DRUG | - |
| kidney transplantation | PROCEDURE | - |
Inclusion Criteria: * renal transplant recipients of the Giessen renal transplant unit * cadaveric and living renal transplants * first and retransplants Exclusion Criteria: * Contraindications against blood-taking (anaemia with hemoglobin \< 9,5 g/l, hypotension) * intravenous immunoglobulin the...
Immunoglobulins is an investigational small molecule being studied for use in chronic renal failure, specifically in the context of renal transplantation. It is being evaluated for its immunoregulatory effects as induction therapy in renal transplant recipients. The drug is currently in early Phase 1 clinical development.
Immunoglobulins is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research on this drug for chronic renal failure and renal transplantation. Roche is the sponsor of the ongoing clinical trial for this investigational therapy.
Immunoglobulins is in early Phase 1 clinical development. It has completed one trial, which was an early Phase 1 study. The drug is still investigational and has not been approved by regulatory authorities. It is being studied for its potential use in chronic renal failure and renal transplantation.
Immunoglobulins has been studied in one clinical trial with the identifier NCT00176059. This trial, titled 'Immunoregulatory Effects of Immunoglobulin Induction Therapy in Renal Transplant Recipients,' was an early Phase 1 study that has been completed. The trial enrolled 50 participants with chronic renal failure undergoing renal transplantation.
Immunoglobulins is being studied for its immunoregulatory effects in renal transplant recipients. The drug is intended to modulate the immune system as induction therapy, potentially helping to prevent rejection in patients with chronic renal failure who receive a kidney transplant. Its mechanism of action is not fully detailed in available information.